Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Belumosudil and Rituximab for the Primary Treatment of Extensive Chronic Graft-versus-host Disease

NCT06046248 is registered in ClinicalTrials.gov with Northside Hospital, Inc. as lead sponsor.

NCT NCT06046248
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06046248 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Belumosudil and Rituximab for the Primary Treatment of Extensive Chronic Graft-versus-host Disease
Lead sponsor
Northside Hospital, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
January 29, 2024
Completion date
December 31, 2027
Enrollment
25 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic graft versus host disease